Tokyo University of Agriculture and Technology

Japan Innovation Therapeutics, Inc.

Akane Tanaka

Hiroshi Matsuda

Akira Matsuda

Provided are a therapeutic or prophylactic agent for retinopathy of prematurity (ROP) that is suited to the pathogenic mechanism of ROP and a method of testing for ROP. The therapeutic or prophylactic agent for ROP uses at least one substance from the group consisting of inhibitors against tryptase derived from mast cells and/or mast cell stabilizers as an active ingredient. The testing method for ROP includes detecting a marker substance that can be released by degranulation of mast cells in a biological sample originating from a patient and determining the presence or absence of ROP on the basis of the detected amount of the marker.

Therapeutic or prophylactic agent for retinopathy of prematurity, testing method for retinopathy of prematurity, and screening method for therapeutic or prophylactic substance for retinopathy of prematurity

An oligonucleotide that inhibits the binding of a serine/arginine-rich protein 30c (SRp30c) to a pre-mRNA of a glucocorticoid receptor gene in vivo.

Growing community of inventors

Tokyo, Japan

Akane Tanaka